<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20132">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02071511</url>
  </required_header>
  <id_info>
    <org_study_id>PV4286</org_study_id>
    <nct_id>NCT02071511</nct_id>
  </id_info>
  <brief_title>Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation</brief_title>
  <acronym>ARDEVAT</acronym>
  <official_title>Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis:

      With optimal medical therapy and repeated ablations, an additional renal denervation may
      have protective effects in terms of vegetative intrinsic activity and lead to a significant
      reduction in VT Burdens.

      Study design:

      Multicenter, randomized, prospective, single-blind clinical trial.

      Study protocol:

      Catheter ablation of ventricular tachycardia versus combined catheter ablation of
      ventricular tachycardia and renal denervation.

      A total of 50 patients with ventricular tachycardia treated with ICD shocks or ATP will be
      enrolled in this study. The randomization in the study is done before ablation.

      For the ablation, an arterial access is required in both groups.  During a 30 minutes
      waiting time which will apply to both groups, renal denervation will be performed.

      In this period of time operators and staff will be blinded for the procedure, thereby they
      won't know if the patients will receive a renal denervation, in that way the investigators
      are avoiding a bias of future treatment of the patients.

      Follow up and repeat procedures:

      All Patients will be followed for a period of 3, 6, 9, 12 and 18 months after the procedure.

      Regular visits are done in the investigators office. The visit will include ICD
      Interrogation, VT documentation in ICD Holter, 24-hour Holter ECG or Tele-ECGs,
      echocardiography.

      Re- VT ablations are allowed at any time. In case of renal artery stenosis, denervation will
      not be performed. Drug therapy can be continued.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Patients with adverse events such as recurrens of Ventricular Tachycardias or necessary Intracaridiac shocks during 24 months follow up</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Ventricular extrasystoles and non-sustained Ventricular Tachycardias compared to the time prior to ablation during 24 months follow up</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of periprocedural complications</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ablation of ventricular arrhythmias</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ablation of ventricular arrhythmias + additional renal denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of ventricular arrhythmias</intervention_name>
    <description>control group: Ablation of ventricular Tachycardias</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of Vts + additional renal denervation</intervention_name>
    <description>Intervention group: Ablation of VTs an additional renal denervation</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Ischemic cardiomyopathy

          -  LV-EF ≥ 30%

          -  Recurrent ventricular tachycardia, ICD interventions (shock or ATP)

          -  Obtained written informed consent

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Previous VT ablation

          -  LV-EF ≤ 30%

          -  Cardiopulmonary decompensation within the last 4 weeks

          -  Pregnant women or women of childbearing potential without a negative pregnancy test
             within 48 hours prior to treatment

          -  History of hemorrhagic diathesis or other coagulopathies

          -  Contraindication for oral anticoagulation

          -  Hyper- or hypothyroidism

          -  Drug or chronic alcohol abuse

          -  Has any condition that would make participation not be in the best interest of the
             subject

          -  Incompliants
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Willems, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Willems, MD</last_name>
    <phone>+ 49 40 7410</phone>
    <phone_ext>59471</phone_ext>
    <email>willems@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Boris Hoffmann, MD</last_name>
    <phone>+ 49 40 7410</phone>
    <phone_ext>59471</phone_ext>
    <email>b.hoffmann@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Willems, MD</last_name>
      <phone>+49 40 7410</phone>
      <phone_ext>59471</phone_ext>
      <email>willems@uke.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Willems</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
